Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

CJD risk set to cost blood service pounds 70m

Charles Arthur Science Editor
Wednesday 13 May 1998 23:02 BST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

BRITAIN will have to spend up to pounds 70m a year importing blood plasma products from the US, because of the risk of transmitting "human BSE" through UK-source blood products, following a government decision yesterday.

The measure will significantly raise the costs of the National Blood Service from its present pounds 200m annual budget. It follows a review by the Committee on Safety of Medicines (CSM) on the risk that "new variant" Creutzfeldt-Jakob disease (v-CJD), caused by the BSE infective agent, could be passed in plasma.

Instead, more than 300 tonnes of plasma will have to be imported from the US, at a cost of pounds 20m. The MSF union, which represents blood service staff, said the cost of extra precautions needed to filter donated blood in future would amount to around pounds 50m.

The CSM decided that "although there currently no evidence that v-CJD can be transmitted by blood, there is nevertheless a theoretical risk". No tests exist for the presence of the agent in plasma, but scientists suspect that it somehow attaches itself to white blood cells - commonly found in plasma.

Plasma products have a wide variety of uses, including the treatment of burns, and preventive treatments for hepatitis. In December, the Department of Health admitted that up to 3,000 people in 100 hospitals could have been treated with products made from plasma donated by a person who died of v-CJD.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in